Preliminary Final Report

• Income from ordinary activities increased by 214.6% to $559,080
• Loss from ordinary activities after tax increased by 151.1% to $(9,843,987)
• No dividends paid, recommended, or declared during the financial period
• Audit opinion issued was unmodified

Island Pharmaceuticals Ltd released its preliminary final report for the year ended 30 June 2026, showing an increase in income from ordinary activities by 214.6% to $559,080. However, the loss from ordinary activities after tax increased by 151.1% to $(9,843,987). The company did not pay, recommend, or declare any dividends during the financial period. The financial statements were audited and received an unmodified opinion.

Income from ordinary activities: $559,080; Loss after tax: $(9,843,987) for the year ended 30 June 2026